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ABSTRACT 
In the last decade, interest in developing a combination of two or more Active Pharmaceutical Ingredients (API) in a single dosage form (bi -
layer tablet) has increased in the pharmaceutical industry, promoting patient convenience and compliance. The Bi-layer tablets have been 
developed to achieve controlled delivery of different drugs with pre-defined release profiles. Bi-layer tablets can be a primary option to avoid 
chemical incompatibilities between API by physical separation, and to enable the development of different drug release profiles (immediate 
release with extended release). Despite their advantages, due to the use of different materials and complex geometric boundaries between the 
adjacent layers, the mechanical structures of this drug delivery system have become quite intricate, requiring complicated tablet architectures 
as well as patient-friendly. Bi-layer tablets offer definite advantages over conventional release formulation of the same drug. Several 
pharmaceutical companies are currently developing bi-layer tablets. For a variety of reasons: patent extension, therapeutic, marketing to name 
a few. To reduce capital investment, quite often existing but modified tablet presses are used to develop and produce such tablets. 
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INTRODUCTION 
A tablet is mixture of active substance and excipients usually 
in powder form pressed or compacted into a solid. The 
excipients includes binders, glidents (flow-aids), and 
lubricants to ensure efficient tableting, disintigrants to 
ensure that the tablet breaks up in the digestive tract; 
sweeteners or flavours to mask the taste of the bad tasting 
active ingredients and pigments to make uncoated tablets 
visually attractive. A coating may be applied to hide the taste 
of tablets components, to make the tablet smoother and 
easier to swallow and to make it more resistant to 
environment extending its self life. 
PREPARATION AND CHARACTERIZATION METHOD 
17-19 
1) Selection of Method for Compression: 
The major challenge for tablet manufacture comes from the 
powder characteristics of material compressed. There are 
number of compression technology available in 
pharmaceutical industry. Tablets have been made by 
granulation, a process that imparts to be primary requisite to 
formulation for fluidity and compatibility on these bases 
granulation process can be divided as: 
 Dry granulation method. 
 Direct compression. 
 Wet granulation. 
Direct compression: 
The term “direct compression” is defined as the process by 
which tablets are compressed directly from powder mixture 
of API and suitable excipients. No pretreatment of the 
powder blend by wet or dry granulation procedure is 
required. 
2) Formulation Development: 
Preparation of Instant Layer of Sofosbuvir (Phase-1) 
Fast dissolving tablets of Sofosbuvir were prepared by direct 
compression method after incorporating different super 
disintegrants such as, crosscarmellose sodium (Ac-Di-Sol), 
crospovidone and sodium starch glycolate in different 
concentrations. The ingredients given below were weighed 
and mixed in geometric progression in a dry and clean 
mortar. Then the ingredients were passed through mesh 
#60. 
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Magnesium  stearate  as lubricant and  talc as glidant were  
added  in  a  final  step and mixed,  this  blend was  subjected  
to  analysis  of  pre-compression parameters which included 
Angle of repose, Bulk density, Tap density, Carr’s index and 
Hausner’s ratio. 
The Blend was compressed on 8 mm (diameter) fat punches 
on a ‘Rimek mini press 16 station rotary compression 
machine. Eight formulations of Ranitidine hydrochloride 
granules were prepared and  each  formulation  contained  
one  of  the  three  disintegrant  in  different concentration. 
Each tablets weighing 150mg, were obtained. Composition of 
tablets is mentioned in Table 1. 
 
 
Table 1: Composition of Sofosbuvir Fast Dissolving Tablets 
Ingredients(mg) 
Formulation code 
IF1 IF 2 IF 3 IF 4 IF 5 IF 6 IF 7 IF 8 IF 9 
Sofosbuvir 100 100 100 100 100 100 100 100 100 
Sodium Starch glycolate 10 15 20 - - - - - - 
Croscarmellose sodium - - - 10 15 20 - - - 
Crospovidone - - - - - - 10 15 20 
Microcrystalline  cellulose 29 24 19 29 24 19 29 24 19 
Talc 5 5 5 5 5 5 5 5 5 
Magnesium stearate 6 6 6 6 6 6 6 6 6 
Total weight 150 150 150 150 150 150 150 150 150 
 
Evaluation of Precompression Parameter 20-21 
1. Bulk density:  Both loose bulk density (LBD) and 
tapped bulk density (TBD) were determined. 
Accurately weighed amount of granules  taken  in a 50 
ml capacity measuring cylinder was  tapped for  100  
times  on  a  plane  hard wooden  surface  and  
estimated  the LBD  and  TBD,  calculated  by  using  
following  formulas. 
 
 
2. Carr’s Compressibility  Index:  Percent  
compressibility  of  powder mix was determined by 
Carr’s compressibility index, calculated by using 
following formula:- 
 
3. Hausners ratio: It  is determined by comparing tapped 
density to the bulk density by     using following 
equation:- 
Housner’s ratio = Tapped bulk density/loose Bulk density 
Hausner’s ratio value <1.25 shows better flow properties
 
Table 2: Results of pre-compressional parameters of Sofosbuvir 
Formulatio
n code 
Parameters 
Loose Bulk 
density(gm/ml) 
Tapped bulk 
density(gm/ml) 
Carr’s Index 
(%) 
Hausner’s Ratio 
IF1 0.42 0.52 19.231 1.238 
IF2 0.45 0.55 18.182 1.222 
IF3 0.48 0.54 11.111 1.125 
IF4 0.46 0.52 11.538 1.130 
IF5 0.45 0.58 22.414 1.289 
IF6 0.43 0.56 23.214 1.302 
IF7 0.42 0.54 22.222 1.286 
IF8 0.43 0.53 18.868 1.233 
IF9 0.45 0.49 8.163 1.089 
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Figure 4: Graphical representation of Results of pre-compressional parameters of Sofosbuvir 
 
Evaluation of post compression Parameter 
1. Shape and colour of tablets: 
Uncoated tablets were examined under a lens for the shape 
of the tablet and colour was observed by keeping the tablets 
in light22 
2. Thickness test 
Three tablets were picked from each formulation randomly 
and thickness was measured individually. It is expressed in 
mm and standard deviation was also calculated. The tablet 
thickness was measured using dial-caliper (Mitutoyo, Japan). 
3. Weight variation test 
Twenty tablets were selected randomly from each 
formulation and average weight was determined.  The 
tablets were weighed individually and compared with 
average weight. The U.S Pharmacopoeia allows a little 
variation in the weight of a tablet. The following percentage 
deviation in weight variation is allowed. 
4. Hardness test 
The hardness of tablet was measured by Pfizer hardness 
tester and results were expressed in Kg/cm2. 
5. Friability test 
For this, 20 tablets were taken from each formulation and 
the friability was determined using Roche friabilator. The 
equipment was run for 4 min at 25 revolutions per minute. 
The tablets were taken out, dedusted and reweighted and % 
friability was calculated. The friability was determined as 
the mass loss in percent according to Equation:- 
 
The test complies if tablets not lose more than 1% of their 
weight 
6. Uniformity of drug content: 
The test is mandatory for tablets with 10 mg or less weight 
of active ingredient. Ten randomly selected tablets from 
each formulation (F1 to F9) were finely powdered and Drug 
equivalent  to  10 mg of drug dissolved in 10 ml 0.1 N HCL  
(simulated gastric ﬂuid  of pH 1.2 without enzymes) 
sonicated it for 20 minutes,  till  the  entire  drug leached  out  
from  complex,  then  the  solution was  filtered  through  
what man  filter  paper No. 41. From this Solution take 1 ml 
and Diluted up to 100 ml with 0.1N HCL and the drug 
content was determined spectrophotometrically at 264.0 nm 
for Sofosbuvir. 
 
Table 3: Results of Post-Compression parameters of all formulations 
F. Code Hardness 
test (kg/cm2) 
Friability 
(%) 
Weight Variation 
(%) 
Thickness 
(mm) 
Drug content (%) 
 
IF1 3.5 0.856 152 2.35 96.65 
IF2 3.6 0.845 153 2.36 98.89 
IF3 3.4 0.898 150 2.45 98.52 
IF4 3.9 0.856 154 2.32 97.65 
IF5 3.7 0.874 148 2.25 98.98 
IF6 3.5 0.856 149 2.41 98.12 
IF7 3.4 0.856 152 2.32 97.85 
IF8 3.5 0.789 152 2.43 98.78 
IF9 3.4 0.795 153 2.43 98.85 
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Figure 5: Graphical Representation of Post-Compression parameters of all formulations 
 
Method for Preparation of Sofosbuvir Floating Gastro-
retentive tablet 23 
Direct compression- was followed to manufacture the gas 
generating floating tablets of Sofosbuvir .Nine different 
formulations (F1, F2, F3, F4, F5, F6, F7, F8, & F9) were 
prepared by direct compression. All the polymers selected, 
drug and excipients were passed through sieve no. 40 before 
using into formulation. The amount and ratio of drug and 
polymers were weighed as per given in table No.4 and all the 
formulation were used for further evaluations parameters. 
Polymers selected for tablets are- 
 HPMC K 15, 
 HPMC K4, 
 PVP K30 
 
 
Optimization of Gastro retentive floating tablets of Sofosbuvir floating tablets 
Table 4: Various formulations of Sofosbuvir gastro retentive tablets 
 
Excipients like Sodium bicarbonate, citric acid anhydrous, 
Magnesium Stearate were selected for the study. Sodium 
bicarbonate and citric acid were used as gas generating 
agent. Citric acid was also used as an antioxidant. Steps 
involved in the manufacture of tablets, first the drug, 
polymer and other excipients selected were passed through 
40-mesh sieve. Required quantity of drug, polymer and 
excipients were weighed properly and transferred into 
polyethylene bag and the blend was mixed for at least 15 
min. The blend obtained was then lubricated by adding 1% 
magnesium stearate and again mixed for another 5 min. 
Evaluation of tablets:- 
All the tablets were evaluated for following different 
parameters which includes; 
1. General Appearance 
Five tablets from different batches were randomly selected 
and organoleptic properties suchas color, odor, taste, shape, 
Excipients(mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Sofosbuvir 300 300 300 300 300 300 300 300 300 
HPMC K 15 _ _ _ 80 100 120 40 50 60 
HPMC K 4 80 100 120 _ _ _ 40 50 60 
PVP K30 15 15 15 15 15 15 15 15 15 
Citric acid 5 5 5 5 5 5 5 5 5 
NaHCO3 20 20 20 20 20 20 20 20 20 
Mg(C18H35O2)2 5 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 5 
Lactose 70 50 30 70 50 30 70 50 30 
Total Weight 500 500 500 500 500 500 500 500 500 
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were evaluated. Appearance was judged visually.Very good 
(+++), good (++), fair (+) poor (-), very poor (- -). 
2. Thickness and diameter 
Thickness and diameter of tablets were determined using 
Vernier caliper. Five tablets fromeach batch were used, and 
an average value was calculated. 
3. Drug content 
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 100 mg of drug was 
transferred to 100 ml standard flask. The powder was 
dissolved in 50 ml of 0.1 N HCL and made up to volume with 
of 0.1 N HCL. The sample was mixed thoroughly and filtered 
through a 0.45μ membrane filter. The filtered solution was 
diluted suitably and reacts with dye and analyzed for drug 
content by UV spectrophotometer at a λ max of 264.0 nm 
using of 0.1 N HCL as blank. 
4. Hardness 
For each formulation, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach) 
5. Friability 
The friability of a sample of 10 tablets was measured using a 
Friability tester (Electro Lab).Ten tablets were weighed, 
rotated at 25 rpm for 4 minutes. Tablets were reweighed 
afterremoval of fines (dedusted) and the percentage of 
weight loss was calculated. 
6. Uniformity of weight 
Twenty tablets were randomly selected from each batch 
individually weighed, the average weight and standard 
deviation of 20 tablets was calculated. 
7. In vitro buoyancy studies: 
In vitro buoyancy was determined by floating lag time as per 
the method described below. The tablets were placed 
separately ina100 ml glass beaker containing simulated 
gastric fluid (SGF), pH1.2 as per USP. The time required for 
the tablet to rise to the surface and float was determined as 
floating lag time. 
8. Dissolution rate studies 
In vitro drug release of the sample was carried out using 
USP- type II dissolution apparatus (Paddle type). The 
dissolution medium, 900 ml 0.1N HCL was placed into the 
dissolution flask maintaining the temperature of 37±0.50ºc 
and rpm of 75.One Sofosbuvir tablet was placed in each 
basket of dissolution apparatus. The apparatus was allowed 
to run for 10 hours. Sample measuring 5 ml were withdrawn 
after every 1 hour up to 10 hours using 10 ml pipette. The 
fresh dissolution medium (370C) was replaced every time 
with the same quantity of the sample. From this take 0.5 ml 
and dilute up to 10 ml with 0.1 N HCL and take the 
absorbance at 264 nm using spectroscopy. 
 
Table 5: Results of Post Compression Properties of Sofosbuvir FGR Tablets 
Formulati
on code 
Thickness 
(mm) 
Hardness 
(kg/cm2) 
Weight 
variation (mg) 
Friability (%) Drug content 
(%) 
F1 3.95 5.2 505 0.895 98.85 
F2 3.85 5.3 510 0.852 98.99 
F3 3.68 5.4 508 0.789 98.65 
F4 3.78 5.2 505 0.856 97.89 
F5 3.85 5.4 506 0.745 98.45 
F6 3.78 5.2 504 0.658 99.56 
F7 3.82 5.3 498 0.980 98.89 
F8 3.68 5.1 495 0.965 98.78 
F9 3.45 5.2 508 0.745 99.12 
 
 
Figure 6: Graph of In-vitro Drug Release Study of GRF Tablets 
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In vitro drug release study of Gastro retentive floating tablet: 
Tablet 6: In-vitro Drug Release Study of GRF Tablets 
Time % Cumulative Drug Release 
(hr) F1 F2 F3 F4 F5 F6 F7 F8 F9 
0.5 39.78 36.65 33.45 30.12 25.65 22.35 18.56 15.23 11.56 
1 45.65 43.23 40.45 38.78 35.65 36.65 30.25 25.65 20.32 
1.5 59.98 55.45 52.56 50.12 49.98 45.58 35.65 30.45 26.65 
2 75.56 69.98 65.65 63.32 62.12 56.65 42.25 36.65 31.47 
3 82.45 80.45 78.89 75.65 73.65 65.89 53.65 45.65 43.65 
4 95.65 92.25 90.25 88.98 84.65 73.45 68.98 58.98 55.45 
6  98.78 96.65 93.65 90.12 88.98 70.12 65.78 60.12 
8   98.89 98.89 97.45 95.65 78.98 73.32 68.78 
12      99.12 89.98 81.45 79.98 
 
Formulation development of bi-layer tablet25 
Optimized formulation IF-7 of Instant release layer and 
optimized formulation of F-6 for control release used for 
formulation of Bi-layer tablet. 
Evaluation of bi-layer tablets- 
All the tablets were evaluated for following different 
parameters which includes; 
1. General Appearance24 
Five tablets from different batches were randomly selected 
and organoleptic properties such as color, odor, taste, shape, 
were evaluated. Appearance was judged visually. 
Very good (+++), good (++), fair (+) poor (-), very poor (- -). 
2. Thickness and diameter 
Thickness and diameter of tablets were determined using 
Vernier caliper. Five tablets fromeach batch were used, and 
an average value was calculated. 
3. Hardness 
For each formulation, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach). 
4. Friability 
The friability of a sample of 10 tablets was measured using a 
Friability tester (Electro Lab).Ten tablets were weighed, 
rotated at 25 rpm for 4 minutes. Tablets were reweighed 
after removal of fines (dedusted) and the percentage of 
weight loss was calculated. 
5. Uniformity of weight 
Twenty tablets were randomly selected from each batch 
individually weighed, the average weight and standard 
deviation of 20 tablets was calculated. 
6. Drug content 
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 5 mg of Sofosbuvir was 
transferred to 10 ml standard flask. The powder was 
dissolved in 10 ml of 0.1 N HCL and made up to volume with 
0.1 N HCL. The sample was mixed thoroughly and filtered 
through a 0.45μ membrane filter. The filtered solution was 
further diluted 0.2 ml to 10 ml suitably 10 ppm solutions 
and determines the Concentration of drug at 264 nm. 
7. Dissolution rate studies- 
In vitro drug release was performed according to the USP 
dissolution apparatus II at 50 rpm and 37±0.5ºC 
temperature over a 12 hrs period for Sofosbuvir bi-layer 
tablets using an automated paddle dissolution system 
(Labindia). A minimum of 6 tablets per batch were tested. 
The media used was 0.1N HCL at a pH 1.2 and a volume of 
900 ml was maintained at 37±0.5◦C. Test sample (1ml) was 
withdrawn at particular time interval and replaced with 
fresh dissolution media maintained at the same temperature 
and the concentration of dissolved drug was determined 
using U.V. (Labindia 3000 plus) spectrophotometer at λ max 
264 nm. 
SUMMARY ANA CONCLUSION 
Preliminary study showed that sofosbuvir is White to off 
white powder and odourless powder. It is freely soluble in 
methanol and ethanol, soluble in 0.1 N HCL, sparingly 
soluble in 0.1 N NaOH, The melting point was in the range of 
198oC which is compliance with the standard value. 
Identification of Sofosbuvir was performed by UV/VIS 
Spectroscopy. The 10 µg/ml solutions of Sofosbuvir was 
scanned in the range of 200-400nm to determine the λ max 
for drug. The λ max of sofosbuvir was found to be 264 nm. 
From the respective stock solution (1mg/ml) different 
concentration of 5, 10, 15, 20 and 25µg/ml Sofosbuvir was 
prepared and scanned in UV region. Their absorbances were 
noted at 264.0 nm and calibration curve was plotted as 
absorbance vs concentration and their linearity range was 
determined. From the FT-IR data of the physical mixture 
obviously function of drug have stayed unaltered including 
forces of the peak. This proposes and the procedure drug 
and excipient has not responded with the drug to offer 
ascent to reactant items. So there is no interaction between 
them which is in favour to proceed for formulation of 
vesicular drug delivery system. Preformulation studies 
reported that the formulation of floating of Sofosbuvir can 
be prepared with appropriate methods. A study involving 
preparation and evaluation of bi-layer tablets of Sofosbuvir 
were made. Physico-chemical parameters of bi-layer tablets 
were performed. In vitro drug release profiles of bi-layer 
tablets were performed. A dissolution study shows the 
release of Sofosbuvir. The Instant layer of sofosbuvir release 
approx 98.32% drug within 15 minutes and control floating 
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layer sofosbuvir shows release up to 12 Hours Approx 99.12 
% of Drug release in 12 hour. 
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